Have another look at this conjunctivitis study, released in June 21.
www.ncbi.nlm.nih.gov/pmc/articles/PMC8201124/
What caught my eye was this. According to Jeremy Paul et all:-
“Further development of astodrimer sodium as a topical antiviral therapy for adenoviral ocular infections is indicated.“
Not “Commercialisation”, but “Further development”. After how many years?!
I am sure some employees still think Starpharma is still a government research centre, funded for ever by the general public.
Ann: US patent issued for DEP cabazitaxel nanoparticle, page-24
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $5.703K | 58.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.41pm 11/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |